Abstract
The integration of artificial intelligence (AI) into ophthalmic drug discovery and development presents transformative opportunities to address the inherent complexities and challenges of creating targeted therapies for eye diseases. The ability of AI to process vast datasets can facilitate the discovery of novel drug candidates, improve predictions of drug efficacy and safety, and streamline the drug development pipeline. Applications can range from enhancing target identification and compound screening to refining predictive toxicology. However, challenges such as data limitations, computational demands, model interpretability, and ethical considerations remain. Despite these hurdles, the integration of AI with emerging technologies and its potential to optimize clinical trials signifies a new era of innovation in ophthalmology, emphasizing its critical role in addressing current challenges and advancing therapeutic development. In this paper, we explore the role of AI in ophthalmic drug discovery, highlighting its potential to address critical challenges in the field and delineating its impact across various stages of drug development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
